Zhang Yanan, Ruan Fang
Department of Obstetrics and Gynecology, Affiliated Hospital of Jining Medical College, Jining 272000, People's Republic of China.
Cancer Manag Res. 2020 Jan 30;12:687-694. doi: 10.2147/CMAR.S227652. eCollection 2020.
Growing evidence indicates that long noncoding RNA (lncRNA) is a group of important regulator in cancer development. However, the correlation between lncRNA and ovarian cancer remains elusive. Here, we aimed to investigate the roles of LEF1-AS1 in ovarian cancer progression.
LEF1-AS1 expression was analyzed by quantitative real-time polymerase chain reaction (qRT-PCR). Survival rate was analyzed by Kaplan-Meier method. Cell Counting Kit-8 (CCK8) and colony formation assays were used for proliferation analysis. Transwell assay was utilized for analyses of migration and invasion. Luciferase reporter assay was performed to test the interaction between LEF1-AS1 and miR-1285-3p.
We showed that LEF1-AS1 expression was upregulated in ovarian cancer tissues compared with normal tissues. Besides, LEF1-AS1 level was positively correlated with lymph node metastasis and advanced stage. Enhanced expression of LEF1-AS1 may predict a poor prognosis. Moreover, LEF1-AS1 knockdown suppressed ovarian cancer cell proliferation, migration and invasion. Mechanistically, LEF1-AS1 exerted its oncogenic functions through interacting with miR-1285-3p to inhibit miRNA activity. Rescue assay validated that miR-1285-3p inhibitors abrogated LEF1-AS1-silencer-caused suppression of ovarian cancer progression.
Our study revealed that LEF1-AS1 acts as a vital regulation in ovarian cancer progression.
越来越多的证据表明,长链非编码RNA(lncRNA)是癌症发展中的一组重要调节因子。然而,lncRNA与卵巢癌之间的相关性仍不清楚。在此,我们旨在研究LEF1-AS1在卵巢癌进展中的作用。
通过定量实时聚合酶链反应(qRT-PCR)分析LEF1-AS1的表达。采用Kaplan-Meier法分析生存率。使用细胞计数试剂盒-8(CCK8)和集落形成试验进行增殖分析。Transwell试验用于分析迁移和侵袭。进行荧光素酶报告基因试验以检测LEF1-AS1与miR-1285-3p之间的相互作用。
我们发现,与正常组织相比,卵巢癌组织中LEF1-AS1的表达上调。此外,LEF1-AS1水平与淋巴结转移和晚期呈正相关。LEF1-AS1表达增强可能预示预后不良。此外,LEF1-AS1基因敲低抑制了卵巢癌细胞的增殖、迁移和侵袭。机制上,LEF1-AS1通过与miR-1285-3p相互作用发挥其致癌功能,从而抑制miRNA活性。挽救试验证实,miR-1285-3p抑制剂可消除LEF1-AS1沉默剂引起的对卵巢癌进展的抑制作用。
我们的研究表明,LEF1-AS1在卵巢癌进展中起重要调节作用。